ArticleJournal of nanobiotechnology2025
Amelioration of the rheumatoid arthritis microenvironment using celastrol-loaded silver-modified ceria nanoparticles for enhanced treatment.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Dynamic microenvironment-regulated hydrogels releasing celastrol lead to urethral scarless repair.Materials today. Bio · 2026Article
- Programmable ROS modulation by nanomedicine for rheumatoid arthritis treatment.Materials today. Bio · 2026Review
- Theranostic Nanoprobes for Rheumatoid Arthritis: From Inflammation Visualization to Guided Precision Therapy.International journal of nanomedicine · 2026Review
- Engineering nanoparticles for macrophage reprogramming in chronic inflammatory diseases: current advances, challenges, and future perspectives.Frontiers in bioengineering and biotechnology · 2026Review
- Nanozyme-Based Anti-Inflammatory Strategies in Cardiovascular Disease Management: Clinical Prospects and Challenges.International journal of nanomedicine · 2026Review
- Nanomedicine Strategies for Rheumatoid Arthritis: Precision Delivery and Immune Microenvironment Modulation.International journal of nanomedicine · 2026Review
- Injectable Hyaluronic Acid-Functionalized Nanocomposite Hydrogel for Targeted Rheumatoid Arthritis Therapy via Concurrent ROS Attenuation and Macrophage Repolarization.International journal of nanomedicine · 2026Article
- Nanozymes for Bone Regeneration: Mechanistic Insights into Immune and Metabolic Microenvironment Modulation.International journal of nanomedicine · 2026Review
- Nanoceria as Next-Generation Immunotherapeutics: Applications in Chronic Inflammation, Cancer, and Tissue Repair.Journal of nanotheranostics · 2025Article
- Trace Elements-Role in Joint Function and Impact on Joint Diseases.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is characterized by elevated levels of reactive oxygen species (ROS) and a persistent inflammatory microenvironment dominated by M1 macrophages, both of which contribute to disease progression. To address these pathological features, we developed a core-shell nanoplatform consisting of silver-modified ceria nanoparticles loaded with celastrol (Ag-CeNP@Cel). This nanoplatform significantly enhances the water solubility of celastrol and reduces its hepato-renal toxicity by enabling passive accumulation in inflamed joints. The silver-modified ceria nanoparticles synergistically combine with celastrol to scavenge excess ROS and reprogram M1 macrophages into M2 macrophages, thereby mitigating inflammatory responses and improving the rheumatoid arthritis microenvironment (RAM). Ag-CeNP@Cel exhibited robust therapeutic efficacy and safety in preclinical models, presenting an innovative approach to RA treatment by integrating ROS elimination with macrophage modulation to ameliorate inflammatory microenvironment. This study underscores the potential of Ag-CeNP@Cel as a promising therapeutic strategy for RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.